Drug Rash Eosinophilia Systemic Symptoms (DRESS) syndrome is a systemic hypersensitivity reaction characterized by exfoliative dermatitis and maculopapular rash, lymphadenopathy, fever, eosinophilia, leukocytosis, and involvement of internal organs as liver, lung, heart, and kidney; the disorder starts within 2–6 weeks after taking a drug with an incidence that ranges from 1/1000 to 1/10000 exposures. Fatal cases are reported. The exact pathogenesis of DRESS syndrome is not completely understood, while it is reported that amoxicillin could trigger it in patients who are taking allopurinol, sulfasalazine, NSAIDs, carbamazepine, strontium ranelate, lisinopril, lansoprazole, and minocycline. Amoxicillin could act directly, inducing the reactivation of a viral infection (HHV 6 and EBV) with symptoms similar to DRESS syndrome or by reducing the patients’ ability to detoxify the body from substances chronically taken. We describe a case of a patient admitted to our hospital for a DRESS syndrome flared after amoxicilline intake during treatment with sulfasalazine; this combination can activate severe reactions often with an insidious onset that can mimic an infectious disease. 1. Case Report A 53-year-old woman, Caucasian, without history of drug intolerance, heavy smoker, affected by remote diagnosis of Lyme disease, previous removal of ovarian cyst, and gastroesophageal reflux, was diagnosed in another hospital as having a seronegative spondyloarthritis with anterior right uveitis. For this reason sulfasalazine was started until the dosage of 2 grams per day; after six weeks of treatment, amoxicillin/clavulanic acid was administered for the onset of sore throat, fever and laterocervical lymphadenopathy, and sulfasalazine suspended. After 3 days, she was admitted to our hospital for an acute diffuse and itchy rash with hemorrhagic vesicles on oral cavity, facial edema, and worsening of lymphadenopathy and fever. On admission mental status was normal, body temperature was 39.2°C, blood pressure was 130/80, and the heart and respiratory rates were, respectively, 115 beats and 22 acts per minute. Laboratory tests showed neutrophilic leukocytosis with mild eosinophilia (WBC: 12200/mmc, PMNn: 8580/mmc, and Eo: 690/mmc), AST: 106?IU/L (nv < 30?IU/L), ALT: 350 IU/L (nv < 30?IU/L), GGT: 1047?IU/L (nv 5–36?IU/L), alcaline phosphatase: 2959?IU/L (nv < 240?IU/L), total bilirubin: 2,71?mg/dL (nv < 1.0?mg/dL), C-reactive protein 112?mg/L, (nv < 5.0?mg/L), and ERS 103?mm/1 hour; serum creatinine, glucose, calcium, Na eK, TSH, total gamma globulins, IgG/A/M, K/Lambda chain
References
[1]
M. Rudwaleit, D. van der Heijde, M. A. Khan, J. Braun, and J. Sieper, “How to diagnose axial spondyloarthritis early,” Annals of the Rheumatic Diseases, vol. 63, no. 5, pp. 535–543, 2004.
[2]
P. Cacoub, P. Musette, V. Descamps et al., “The DRESS syndrome: a literature review,” The American Journal of Medicine, vol. 124, no. 7, pp. 588–597, 2011.
[3]
H. Bocquet, M. Bagot, and J. C. Roujeau, “Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS),” Seminars in Cutaneous Medicine and Surgery, vol. 15, no. 4, pp. 250–257, 1996.
[4]
S. H. Kardaun, A. Sidoroff, L. Valeyrie-Allanore et al., “Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?” British Journal of Dermatology, vol. 156, no. 3, pp. 609–611, 2007.
[5]
T. Shiohara, M. Iijima, Z. Ikezawa, and K. Hashimoto, “The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations,” British Journal of Dermatology, vol. 156, no. 5, pp. 1083–1084, 2007.
[6]
C. H. Wei, R. Chung-Yee Hui, C.-J. Chang et al., “Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (Dress),” European Journal of Dermatology, vol. 21, no. 6, pp. 930–937, 2011.
[7]
P. E. Pellett, D. V. Ablashi, P. F. Ambros et al., “Chromosomally integrated human herpesvirus 6: questions and answers,” Reviews in Medical Virology, vol. 22, no. 3, pp. 144–155, 2012.
[8]
H. Peyrière, O. Dereure, H. Breton et al., “Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?” British Journal of Dermatology, vol. 155, no. 2, pp. 422–428, 2006.
[9]
G. Bahat, H. G. Celik, F. Tufan, and B. Saka, “Drug rash with eosinophilia and systemic symptoms syndrome induced by sulfasalazine,” Joint Bone Spine, vol. 77, no. 1, pp. 87–88, 2010.
[10]
I. Bejia, S. Ben Hammouda, K. Riahi et al., “DRESS syndrome induced by sulphasalazine in rheumatoid arthritis,” Joint Bone Spine, vol. 73, no. 6, pp. 764–765, 2006.
[11]
R. T. R. de Aquino, C. S. V. Vergueiro, M. E. R. Magliori, and T. H. P. de Freitas, “Sulfasalazine-induced DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms),” Sao Paulo Medical Journal, vol. 126, no. 4, pp. 225–226, 2008.
[12]
N. B. Fredj, K. Aouam, A. Chaabane et al., “Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization,” British Journal of Clinical Pharmacology, vol. 70, no. 2, pp. 273–276, 2010.
[13]
K. Aouam, A. Chaabane, A. Toumi et al., “Drug rash with eosinophilia and systemic symptoms (DRESS) probably induced by cefotaxime: a report of two cases,” Clinical Medicine and Research, vol. 10, no. 1, pp. 32–35, 2012.
[14]
J. Jurado-Palomo, R. Caba?as, N. Prior et al., “Use of the lymphocyte transformation test in the diagnosis of DRESS syndrome induced by ceftriaxone and iperacillintazobactam: two case reports,” Journal of Investigational Allergology and Clinical Immunology, vol. 20, no. 5, pp. 433–436, 2010.
[15]
L. Mardivirin, L. Valeyrie-Allanore, E. Branlant-Redon et al., “Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on human herpesvirus 6 replication in vitro,” European Journal of Dermatology, vol. 20, no. 1, pp. 68–73, 2010.
[16]
Y. Kano, M. Inaoka, K. Sakuma, and T. Shiohara, “Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome,” Toxicology, vol. 209, no. 2, pp. 165–167, 2005.
[17]
R. Bourguignon, C. Piérard-Franchimont, P. Paquet, and G. E. Piérard, “DRESS syndrome to sulfasalazine,” Revue Medicale de Liege, vol. 61, no. 9, pp. 643–648, 2006.
[18]
M. Mennicke, A. Zawodniak, M. Keller et al., “Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation: case report,” American Journal of Transplantation, vol. 9, no. 9, pp. 2197–2202, 2009.
[19]
Y. Allanore, L. Moachon, E. Maury, A. Isvy, and A. Kahan, “Bosentan-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome,” Journal of Rheumatology, vol. 37, no. 5, pp. 1077–1078, 2010.
[20]
D. A. Khan and R. Solensky, “Drug allergy,” Journal of Allergy and Clinical Immunology, vol. 125, no. 2, pp. S126–S137, 2010.
[21]
F. Michel, J.-C. Navellou, D. Ferraud, E. Toussirot, and D. Wendling, “DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis,” Joint Bone Spine, vol. 72, no. 1, pp. 82–85, 2005.
[22]
E. Mylonakis, C. C. Vittorio, D. A. Hollik, and S. Rounds, “Lamotrigine overdose presenting as anticonvulsant hypersensitivity syndrome,” Annals of Pharmacotherapy, vol. 33, no. 5, pp. 557–559, 1999.
[23]
Y. Tung, B. Escutia, M. Blanes, M. Navarrro, and C. Pujol, “Sulfasalazine-induced hypersensitivity syndrome associated with human herpesvirus 6 reactivation and induction of antiphospholipid syndrome,” Actas Dermo-Sifiliograficas, vol. 102, no. 7, pp. 537–540, 2011.
[24]
M. M. Levy, M. P. Fink, J. C. Marshall et al., “2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference,” Intensive Care Medicine, vol. 29, no. 4, pp. 530–538, 2003.